ArticleChemNanoMat : chemistry of nanomaterials for energy, biology and more2017
Chirality Controls Reaction-Diffusion of Nanoparticles for Inhibiting Cancer Cells.
Article in ChemNanoMat : chemistry of nanomaterials for energy, biology and more, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 32 citations in OpenAlex.
- Self-Assembly of Noncanonical Peptides: A New Frontier in Cancer Therapeutics and Beyond.Macromolecular bioscience · 2025Review
- Considering the impact of the chirality of therapeutic nanoparticles on cancer therapy.Nanomedicine (London, England) · 2024Article
- Chirality-enhanced transport and drug delivery of graphene nanocarriers to tumor-like cellular spheroid.Frontiers in chemistry · 2023Article
- Chiral nanomaterials for tumor therapy: autophagy, apoptosis, and photothermal ablation.Journal of nanobiotechnology · 2021Review
- Chiral Plasmonics and Their Potential for Point-of-Care Biosensing Applications.Sensors (Basel, Switzerland) · 2020Review
- Enzymatic Noncovalent Synthesis of Supramolecular Soft Matter for Biomedical Applications.Matter · 2019Article
- Dynamic Continuum of Molecular Assemblies for Controlling Cell Fates.Chembiochem : a European journal of chemical biology · 2019Article
- Enantiopure polythiophene nanoparticles. Chirality dependence of cellular uptake, intracellular distribution and antimicrobial activity.RSC advances · 2019Article
- Enzymatic Self-Assembly Confers Exceptionally Strong Synergism with NF-κB Targeting for Selective Necroptosis of Cancer Cells.Journal of the American Chemical Society · 2018Article
- Self-Assembling Ability Determines the Activity of Enzyme-Instructed Self-Assembly for Inhibiting Cancer Cells.Journal of the American Chemical Society · 2017Article
- Supramolecular biofunctional materials.Biomaterials · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Reaction-diffusion (RD) is the most important inherent feature of living organism, but it has yet to be used for developing biofunctional nanoparticles (NPs). Here we show the use of chirality to control the RD of NPs for selectively inhibiting cancer cells. We observe that L-phosphotyrosine (L-pY) decorated NPs (NP@L-pYs) are innocuous to cells, but D-pY decorated ones (NP@D-pYs) selectively inhibit cancer cells. Our study shows that alkaline phosphatases (ALP), presented in the culture and overexpressed on the cancer cells, dephosphorylates NP@L-pYs much faster than NP@D-pYs. Such a rate difference allows the NP@D-pYs to be mainly dephosphorylated on cell surface, thus adhering selectively on the cancer cells to result in poly(ADP-ribose)polymerase (PARP) hyperactivation mediated cell death. Without phosphate groups or being prematurely dephosphorylated before reaching cancer cells (as the case of NP@L-pYs), the NPs are innocuous to cells. Moreover, NP@D-pYs even exhibit more potent activity than cisplatin for inhibiting platinum-resistant ovarian cancer cells (e.g., A2780-cis). As the first example of chirality controlling RD process of NPs for inhibiting cancer cells, this work illustrates a fundamentally new way for developing nanomedicine based on RD processes and nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.